Evaluate the Safety and Effectiveness of Sodium Hyaluronate When Used for the Correction of Nasolabial Folds

Inclusion Criteria: * Age 18 to 65 years of male or female * Wrinkle Severity Rating Scale (WSRS) of bilateral nasolabial folds graded 3 or 4 by blinded evaluator (moderate to severe bilateral nasolabial fold), consistent grade of bilateral nasolabial folds, and the grades approved by the physician who perform the treatment * Agree not to undergo any other under-eye facial surgery (including nose) during the study period Exclusion Criteria: * Injection site with infection or other skin diseases present which may affect the evaluation * With medical history of chromatosis, discoloration, keloid formation, hypertrophic scarring at nasolabial folds * With permanent implants or planning to receive permanent implants during the study period at the injection sites * Hyaluronate facial dermal implant injection or other impermanent dermal fillers injection at injection sites within the past 12 months * With under-eye facial Botox or fat injection within the past 6 months or planning to receive under-eye facial Botox or fat injection during the study period * With under-eye facial chemical or lasers peeling, non-invasive skin tightening, thermocool within the past 3 months or planning to receive these aesthetic procedures during the study period * With prescription medication for nasolabial fold treatment, topical corticosteroid, skinirritating topical products or pigmentation products within the past 2 weeks or planning to take these medication or products during the study period * With systemic immunosuppressive therapy or systemic corticosteroids within the past 2 months or planning to receive these therapies during the study period (subjects who have received inhaled/intranasal corticosteroids could be considered to include.) * Severe liver or kidney defects (such as the value of ALT or AST over 1.5 folds of upper limit of normal value; the value of creatinine over 1.5 folds of upper limit of normal value) * With clinical meaningful coagulation disorders, underdoing anticoagulant treatment or within the past 10 days, or taking blood circulation promotion and blood stasis removement medications * With epilepsy or porphyria * With congenital or idiopathic methemoglobinemia or glucose-6-phosphate dehydrogenase deficiency * With the need to take b-blocker during the study period * With severe atrioventricular block (type 2 second-degree AV block and third-degree AV block) * With analgesic dependence, analgesics within the past 2 weeks or planning to receive analgesics during the study period * With orthodontics, tooth extraction, tooth implantation (extraction or implantation of tooth anterior to the second premolar) or planning to receive these procedures during the study * With history of hypersensitivity or allergy to lidocaine, amide anesthetics, hyaluronic acid or any component of the device; Gram-positive bacterial or Streptococcus proteins; other severe hypersensitivity history unsuitable for participating in the study * Planning to undergo any surgery which may cause significant body weight change (such as bariatric surgery) or take any medication which may cause significant body weight change * Pregnant, planning pregnancy or in breastfeeding females * With syphilis or HIV infection * Participated in clinical study of other device or drug and have not terminated within the past 30 days -Other circumstances which judged to be unsuitable for participating in the study by the investigator